All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F12%3A%230001795" target="_blank" >RIV/65269705:_____/12:#0001795 - isvavai.cz</a>

  • Result on the web

    <a href="http://www.biomedcentral.com/1471-2407/12/415" target="_blank" >http://www.biomedcentral.com/1471-2407/12/415</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1186/1471-2407-12-415" target="_blank" >10.1186/1471-2407-12-415</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma

  • Original language description

    Carfilzomib is a next-generation proteasome inhibitor with single-agent activity in patients with relapsed and refractory multiple myeloma (R/R MM). In PX-171-003-A1, a single-arm phase 2 study of carfilzomib monotherapy in heavily pretreated patients, the overall response rate was 23.7%, 37% of patients achieved >= minimal response and median overall survival (OS) was 15.6 months. Based on this study, carfilzomib is under review by the US Food and Drug Administration for approval to treat R/R MM. Herein we describe the trial design and rationale for a phase 3 randomized study, FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study), being conducted to compare OS after treatment with single-agent carfilzomib to best supportive care(BSC) regimen in R/R MM.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2012

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    BMC Cancer

  • ISSN

    1471-2407

  • e-ISSN

  • Volume of the periodical

    2012

  • Issue of the periodical within the volume

    12

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    7

  • Pages from-to

    415-422

  • UT code for WoS article

    000311048500001

  • EID of the result in the Scopus database